Back to top
more

Puma Biotechnology (PBYI)

(Delayed Data from NSDQ)

$2.95 USD

2.95
429,641

+0.10 (3.51%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $2.94 -0.01 (-0.34%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Ultragenyx (RARE) Posts Update From AS Study of GTX-102

by Zacks Equity Research

Ultragenyx (RARE) completes enrollment in the phase I/II study of GTX-102 for the treatment of pediatric patients with AS. Top-line data from the study is expected in the first half of 2024.

C4 Therapeutics (CCCC) Gains 310% in 3 Months: Here's Why

by Zacks Equity Research

C4 Therapeutics (CCCC) shares surge on a licensing deal to develop degrader-antibody conjugates with Merck and positive data from CFT7455 studies.

BEAM Stock Rallies More Than 25% in 3 Months: What Next?

by Zacks Equity Research

BEAM is making good progress with its lead pipeline candidate, BEAM-101, which is being developed for treating sickle cell disease. Also, the recent restructuring efforts are expected to reduce costs.

Here's Why You Should Bet on Rigel Pharmaceuticals (RIGL) Now

by Zacks Equity Research

Here, we discuss some reasons why buying Rigel Pharmaceuticals (RIGL) stock now may turn out to be a prudent move.

Anavex (AVXL) Falls 35% on Mixed Rett Syndrome Study Results

by Zacks Equity Research

Anavex (AVXL) falls 35% on mixed results from the mid to late-stage study of 30 mg ANAVEX2-73 for the treatment of pediatric Rett Syndrome patients aged 5-17 years.

Longboard Pharma (LBPH) Up on Upbeat Data From Epilepsy Study

by Zacks Equity Research

Longboard Pharma (LBPH) skyrockets 316% on positive data from phase Ib/IIa study of bexicaserin for the treatment of seizures associated with a broad range of epilepsy indications.

Puma Biotech (PBYI) Shows Fast-paced Momentum But Is Still a Bargain Stock

by Zacks Equity Research

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Puma Biotech (PBYI) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Here's Why You Should Invest in Aquestive (AQST) Stock Now

by Zacks Equity Research

Here, we discuss some reasons why buying Aquestive Therapeutics (AQST) stock now may turn out to be a prudent move.

Corcept (CORT) Falls on Loss of Korlym Patent Lawsuit to Teva

by Zacks Equity Research

The United States district court for the district of New Jersey rules against Corcept (CORT) in a patent infringement lawsuit against Teva Pharmaceuticals. Stock declines.

Acadia's (ACAD) Nuplazid Sales Drive Growth Amid Competition

by Zacks Equity Research

Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, dependence on Nuplazid sales for revenues, along with stiff competition, remains a woe.

Amicus (FOLD) Banks on Galafold, Overdependence a Concern

by Zacks Equity Research

Amicus' (FOLD) lead drug, Galafold, is witnessing solid uptake since its launch. The drug holds blockbuster potential. However, overdependence on Galafold for revenues remains a concern.

Vaishali Doshi headshot

4 Promising Liquid Stocks to Boost Your Portfolio in 2024

by Vaishali Doshi

Here are four top-ranked liquid stocks, Puma Biotechnology (PBYI), Amphastar Pharmaceuticals (AMPH), Vimeo (VMEO) and Fluor Corporation (FLR), which investors can add to their portfolio for solid gains

Iovance (IOVA) Falls After Clinical Update on Lung Cancer Drug

by Zacks Equity Research

Iovance (IOVA) is likely to pause enrollment in the phase II IOV-LUN-202 study evaluating its tumor infiltrating lymphocyte therapy, LN-145, for treating non-small cell lung cancer. Stock declines.

Coherus (CHRS) Stock Rallies on FDA Nod for Udenyca Onbody

by Zacks Equity Research

The FDA approves Coherus' (CHRS) Udenyca Onbody, an on-body injector presentation of Udenyca (pegfilgrastim-cbqv). Shares of the company rise on the news.

Cytokinetics (CYTK) Up 83% as Cardiomyopathy Drug Meets Goals

by Zacks Equity Research

Cytokinetics (CYTK) reports positive results from its pivotal late-stage study of aficamten in symptomatic obstructive hypertrophic cardiomyopathy patients. The stock rallies 83% in response.

Milestone Pharma (MIST) Down on Regulatory Update for Etripamil

by Zacks Equity Research

Milestone Pharma (MIST) plunges 31% following an RTF letter from the FDA due to insufficient data to begin a substantive review of the regulatory filing for etripamil nasal spray to treat PSVT.

Senti Bio (SNTI) Rises as FDA Clears IND for Cancer Candidate

by Zacks Equity Research

The FDA clears Senti Bio's (SNTI) investigational new drug application for SENTI-202 for the treatment of relapsed/refractory hematologic malignancies, including acute myeloid leukemia. Stock rises.

Cidara (CDTX) Up on EC Nod for Rezzayo in Invasive Candidiasis

by Zacks Equity Research

Cidara's (CDTX) Rezzayo (rezafungin acetate) gets approval from the European Commission for the treatment of invasive candidiasis in adults. The stock rises 11.1%.

Merck (MRK) & Daiichi Sankyo's Lung Cancer ADC Gets Priority Tag

by Zacks Equity Research

Merck (MRK) and Daiichi Sankyo's regulatory filing for HER3-DXd gets the FDA's priority review grant for the treatment of adult patients with lung cancer. A final decision is expected on Jun 26, 2024.

PBYI or TECH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

PBYI vs. TECH: Which Stock Is the Better Value Option?

Bausch Health (BHC) Ulcerative Colitis Drug Meets Primary Goal

by Zacks Equity Research

Bausch's (BHC) amiselimod achieves the primary and key secondary endpoints, including clinical and endoscopic measures, in the double-blind period of a phase II study.

Sanofi (SNY) Discontinues Tusamitamab Ravtansine Cancer Program

by Zacks Equity Research

Sanofi (SNY) stops the development of tusamitamab ravtansine after a phase III study on the candidate for second-line metastatic non-small cell lung cancer fails to meet the primary endpoint.

GSK, Hansoh Ink Deal to Develop Lung Cancer ADC Candidate

by Zacks Equity Research

GSK enters into an exclusive licensing agreement with China-based Hansoh to develop and commercialize the latter's lung cancer candidate, HS-20093.

Immunovant (IMVT) Up on Upbeat Initial Batoclimab GD Study Data

by Zacks Equity Research

Immunovant (IMVT) announces positive initial data from the mid-stage study of batoclimab in patients with Graves' disease. The stock gains 12% in the after-market hours, following the news.

argenx (ARGX) Tanks on Top-Line Data From Pemphigus Study

by Zacks Equity Research

argenx's (ARGX) phase III ADDRESS study, evaluating efgartigimod subcutaneous for treating pemphigus, fails to meet primary and secondary endpoints. Stock falls.